Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients
•Risk of development of a haematological malignancy is 1.5 times higher in cancer patients than in the general population.•Sharp increase for subsequent haematological malignancies was revealed after 1992.•Survival of subsequent haematological malignancies is poorer than survival of a first haematol...
Gespeichert in:
| Veröffentlicht in: | Cancer epidemiology 2021-06, Vol.72, p.101929-101929, Article 101929 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 101929 |
|---|---|
| container_issue | |
| container_start_page | 101929 |
| container_title | Cancer epidemiology |
| container_volume | 72 |
| creator | Pehalova, Lucie Krejci, Denisa Halamkova, Jana Smardova, Lenka Snajdrova, Lenka Dusek, Ladislav |
| description | •Risk of development of a haematological malignancy is 1.5 times higher in cancer patients than in the general population.•Sharp increase for subsequent haematological malignancies was revealed after 1992.•Survival of subsequent haematological malignancies is poorer than survival of a first haematological malignancy.
Numbers of patients who develop subsequent primary tumours have markedly increased recently. This study aimed to carry out a comprehensive analysis documenting the risk of incidence of subsequent haematological malignancies.
The Czech National Cancer Registry was the main data source, containing records of 126,822 haematological malignancies diagnosed in the period 1977–2016. Subsequent haematological malignancies were identified according to IACR rules. Joinpoint regression was employed to assess the time trends. The risk of development of subsequent haematological malignancy was evaluated by the standardised incidence ratio. The Kaplan–Meier curves were used to assess the differences in survival.
Age-standardised incidence of subsequent haematological malignancies increased from 0.5 in 1977 to 9.1 in 2016. In 1992, there was a significant change in the trend: a sharp increase by 7.7 % annually was revealed thereafter. The risk of development of a haematological malignancy was approximately 1.5 times higher in persons with history of any cancer than in the general Czech population. Patients with haematological malignancies – mainly myelodysplastic syndromes, polycythaemia vera and non-Hodgkin lymphoma – were shown to be at the highest risk of developing a subsequent haematological malignancy. While the median survival following a first haematological malignancy was 2.3 years, it was only 1.1 years for subsequent haematological malignancies (p < 0.001).
Our study identified the highest-risk diagnoses in terms of development of subsequent haematological malignancy. The results might be useful to set up correctly follow-up procedures from which cancer patients could benefit. |
| doi_str_mv | 10.1016/j.canep.2021.101929 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2509266783</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1877782121000461</els_id><sourcerecordid>2509266783</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-5a5fa41b8b8c1435118aa6540a285cbb172bfcd56d9ba776f13a27ec128d356d3</originalsourceid><addsrcrecordid>eNp9kUtLAzEUhYMoVqu_QJCAGzetc5NOkhFcSPEFggsV3IVMJlNS5mUyo_jvvbW1CxeuEk6--8g5hJxAMoUExMVyak3juilLGKyUjGU75ACUlBOp-Nvu9s5gRA5jXCaJEADpPhlxriBTXB2Qz2e_aHzpsVVP7RCCw9N1vnC1b6t2gQ8V7VEtLum9cbXpt2ptKqw1jfUuUhNpHPLo3odVgy742oQv2g91O4RIfUNxgHWBdqb3SMQjsleaKrrjzTkmr7c3L_P7yePT3cP8-nFiuZL9JDVpaWaQq1xZmPEUQBkj0llimEptnoNkeWmLVBRZbqQUJXDDpLPAVMFR5WNyvu7bhRZ3i72ufbSuqtC6doiapUnGhEDDED37gy5x-Qa3Q4qpGVMgJFJ8TdnQxhhcqTef1ZDoVS56qX9y0atc9DoXrDrd9B7y2hXbmt8gELhaAw7N-PAu6Ii-omWFD872umj9vwO-AQ3Wob8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2528428167</pqid></control><display><type>article</type><title>Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>ProQuest Central UK/Ireland</source><creator>Pehalova, Lucie ; Krejci, Denisa ; Halamkova, Jana ; Smardova, Lenka ; Snajdrova, Lenka ; Dusek, Ladislav</creator><creatorcontrib>Pehalova, Lucie ; Krejci, Denisa ; Halamkova, Jana ; Smardova, Lenka ; Snajdrova, Lenka ; Dusek, Ladislav</creatorcontrib><description>•Risk of development of a haematological malignancy is 1.5 times higher in cancer patients than in the general population.•Sharp increase for subsequent haematological malignancies was revealed after 1992.•Survival of subsequent haematological malignancies is poorer than survival of a first haematological malignancy.
Numbers of patients who develop subsequent primary tumours have markedly increased recently. This study aimed to carry out a comprehensive analysis documenting the risk of incidence of subsequent haematological malignancies.
The Czech National Cancer Registry was the main data source, containing records of 126,822 haematological malignancies diagnosed in the period 1977–2016. Subsequent haematological malignancies were identified according to IACR rules. Joinpoint regression was employed to assess the time trends. The risk of development of subsequent haematological malignancy was evaluated by the standardised incidence ratio. The Kaplan–Meier curves were used to assess the differences in survival.
Age-standardised incidence of subsequent haematological malignancies increased from 0.5 in 1977 to 9.1 in 2016. In 1992, there was a significant change in the trend: a sharp increase by 7.7 % annually was revealed thereafter. The risk of development of a haematological malignancy was approximately 1.5 times higher in persons with history of any cancer than in the general Czech population. Patients with haematological malignancies – mainly myelodysplastic syndromes, polycythaemia vera and non-Hodgkin lymphoma – were shown to be at the highest risk of developing a subsequent haematological malignancy. While the median survival following a first haematological malignancy was 2.3 years, it was only 1.1 years for subsequent haematological malignancies (p < 0.001).
Our study identified the highest-risk diagnoses in terms of development of subsequent haematological malignancy. The results might be useful to set up correctly follow-up procedures from which cancer patients could benefit.</description><identifier>ISSN: 1877-7821</identifier><identifier>EISSN: 1877-783X</identifier><identifier>DOI: 10.1016/j.canep.2021.101929</identifier><identifier>PMID: 33819838</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Age ; Blood cancer ; Cancer ; Cancer therapies ; Epidemiology ; Haematological malignancies ; Hematology ; Leukemia ; Lymphoma ; Malignancy ; Myelodysplastic syndrome ; Myelodysplastic syndromes ; Non-Hodgkin's lymphoma ; Patients ; Population ; Standardised incidence ratio ; Subsequent primary tumour ; Survival ; Testicular cancer ; Time trends ; Trends ; Tumors</subject><ispartof>Cancer epidemiology, 2021-06, Vol.72, p.101929-101929, Article 101929</ispartof><rights>2021 Elsevier Ltd</rights><rights>Copyright © 2021 Elsevier Ltd. All rights reserved.</rights><rights>2021. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-5a5fa41b8b8c1435118aa6540a285cbb172bfcd56d9ba776f13a27ec128d356d3</citedby><cites>FETCH-LOGICAL-c387t-5a5fa41b8b8c1435118aa6540a285cbb172bfcd56d9ba776f13a27ec128d356d3</cites><orcidid>0000-0002-2644-326X ; 0000-0003-4426-7236</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2528428167?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978,64366,64368,64370,72220</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33819838$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pehalova, Lucie</creatorcontrib><creatorcontrib>Krejci, Denisa</creatorcontrib><creatorcontrib>Halamkova, Jana</creatorcontrib><creatorcontrib>Smardova, Lenka</creatorcontrib><creatorcontrib>Snajdrova, Lenka</creatorcontrib><creatorcontrib>Dusek, Ladislav</creatorcontrib><title>Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients</title><title>Cancer epidemiology</title><addtitle>Cancer Epidemiol</addtitle><description>•Risk of development of a haematological malignancy is 1.5 times higher in cancer patients than in the general population.•Sharp increase for subsequent haematological malignancies was revealed after 1992.•Survival of subsequent haematological malignancies is poorer than survival of a first haematological malignancy.
Numbers of patients who develop subsequent primary tumours have markedly increased recently. This study aimed to carry out a comprehensive analysis documenting the risk of incidence of subsequent haematological malignancies.
The Czech National Cancer Registry was the main data source, containing records of 126,822 haematological malignancies diagnosed in the period 1977–2016. Subsequent haematological malignancies were identified according to IACR rules. Joinpoint regression was employed to assess the time trends. The risk of development of subsequent haematological malignancy was evaluated by the standardised incidence ratio. The Kaplan–Meier curves were used to assess the differences in survival.
Age-standardised incidence of subsequent haematological malignancies increased from 0.5 in 1977 to 9.1 in 2016. In 1992, there was a significant change in the trend: a sharp increase by 7.7 % annually was revealed thereafter. The risk of development of a haematological malignancy was approximately 1.5 times higher in persons with history of any cancer than in the general Czech population. Patients with haematological malignancies – mainly myelodysplastic syndromes, polycythaemia vera and non-Hodgkin lymphoma – were shown to be at the highest risk of developing a subsequent haematological malignancy. While the median survival following a first haematological malignancy was 2.3 years, it was only 1.1 years for subsequent haematological malignancies (p < 0.001).
Our study identified the highest-risk diagnoses in terms of development of subsequent haematological malignancy. The results might be useful to set up correctly follow-up procedures from which cancer patients could benefit.</description><subject>Age</subject><subject>Blood cancer</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Epidemiology</subject><subject>Haematological malignancies</subject><subject>Hematology</subject><subject>Leukemia</subject><subject>Lymphoma</subject><subject>Malignancy</subject><subject>Myelodysplastic syndrome</subject><subject>Myelodysplastic syndromes</subject><subject>Non-Hodgkin's lymphoma</subject><subject>Patients</subject><subject>Population</subject><subject>Standardised incidence ratio</subject><subject>Subsequent primary tumour</subject><subject>Survival</subject><subject>Testicular cancer</subject><subject>Time trends</subject><subject>Trends</subject><subject>Tumors</subject><issn>1877-7821</issn><issn>1877-783X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kUtLAzEUhYMoVqu_QJCAGzetc5NOkhFcSPEFggsV3IVMJlNS5mUyo_jvvbW1CxeuEk6--8g5hJxAMoUExMVyak3juilLGKyUjGU75ACUlBOp-Nvu9s5gRA5jXCaJEADpPhlxriBTXB2Qz2e_aHzpsVVP7RCCw9N1vnC1b6t2gQ8V7VEtLum9cbXpt2ptKqw1jfUuUhNpHPLo3odVgy742oQv2g91O4RIfUNxgHWBdqb3SMQjsleaKrrjzTkmr7c3L_P7yePT3cP8-nFiuZL9JDVpaWaQq1xZmPEUQBkj0llimEptnoNkeWmLVBRZbqQUJXDDpLPAVMFR5WNyvu7bhRZ3i72ufbSuqtC6doiapUnGhEDDED37gy5x-Qa3Q4qpGVMgJFJ8TdnQxhhcqTef1ZDoVS56qX9y0atc9DoXrDrd9B7y2hXbmt8gELhaAw7N-PAu6Ii-omWFD872umj9vwO-AQ3Wob8</recordid><startdate>202106</startdate><enddate>202106</enddate><creator>Pehalova, Lucie</creator><creator>Krejci, Denisa</creator><creator>Halamkova, Jana</creator><creator>Smardova, Lenka</creator><creator>Snajdrova, Lenka</creator><creator>Dusek, Ladislav</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2644-326X</orcidid><orcidid>https://orcid.org/0000-0003-4426-7236</orcidid></search><sort><creationdate>202106</creationdate><title>Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients</title><author>Pehalova, Lucie ; Krejci, Denisa ; Halamkova, Jana ; Smardova, Lenka ; Snajdrova, Lenka ; Dusek, Ladislav</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-5a5fa41b8b8c1435118aa6540a285cbb172bfcd56d9ba776f13a27ec128d356d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Age</topic><topic>Blood cancer</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Epidemiology</topic><topic>Haematological malignancies</topic><topic>Hematology</topic><topic>Leukemia</topic><topic>Lymphoma</topic><topic>Malignancy</topic><topic>Myelodysplastic syndrome</topic><topic>Myelodysplastic syndromes</topic><topic>Non-Hodgkin's lymphoma</topic><topic>Patients</topic><topic>Population</topic><topic>Standardised incidence ratio</topic><topic>Subsequent primary tumour</topic><topic>Survival</topic><topic>Testicular cancer</topic><topic>Time trends</topic><topic>Trends</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pehalova, Lucie</creatorcontrib><creatorcontrib>Krejci, Denisa</creatorcontrib><creatorcontrib>Halamkova, Jana</creatorcontrib><creatorcontrib>Smardova, Lenka</creatorcontrib><creatorcontrib>Snajdrova, Lenka</creatorcontrib><creatorcontrib>Dusek, Ladislav</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer epidemiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pehalova, Lucie</au><au>Krejci, Denisa</au><au>Halamkova, Jana</au><au>Smardova, Lenka</au><au>Snajdrova, Lenka</au><au>Dusek, Ladislav</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients</atitle><jtitle>Cancer epidemiology</jtitle><addtitle>Cancer Epidemiol</addtitle><date>2021-06</date><risdate>2021</risdate><volume>72</volume><spage>101929</spage><epage>101929</epage><pages>101929-101929</pages><artnum>101929</artnum><issn>1877-7821</issn><eissn>1877-783X</eissn><abstract>•Risk of development of a haematological malignancy is 1.5 times higher in cancer patients than in the general population.•Sharp increase for subsequent haematological malignancies was revealed after 1992.•Survival of subsequent haematological malignancies is poorer than survival of a first haematological malignancy.
Numbers of patients who develop subsequent primary tumours have markedly increased recently. This study aimed to carry out a comprehensive analysis documenting the risk of incidence of subsequent haematological malignancies.
The Czech National Cancer Registry was the main data source, containing records of 126,822 haematological malignancies diagnosed in the period 1977–2016. Subsequent haematological malignancies were identified according to IACR rules. Joinpoint regression was employed to assess the time trends. The risk of development of subsequent haematological malignancy was evaluated by the standardised incidence ratio. The Kaplan–Meier curves were used to assess the differences in survival.
Age-standardised incidence of subsequent haematological malignancies increased from 0.5 in 1977 to 9.1 in 2016. In 1992, there was a significant change in the trend: a sharp increase by 7.7 % annually was revealed thereafter. The risk of development of a haematological malignancy was approximately 1.5 times higher in persons with history of any cancer than in the general Czech population. Patients with haematological malignancies – mainly myelodysplastic syndromes, polycythaemia vera and non-Hodgkin lymphoma – were shown to be at the highest risk of developing a subsequent haematological malignancy. While the median survival following a first haematological malignancy was 2.3 years, it was only 1.1 years for subsequent haematological malignancies (p < 0.001).
Our study identified the highest-risk diagnoses in terms of development of subsequent haematological malignancy. The results might be useful to set up correctly follow-up procedures from which cancer patients could benefit.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>33819838</pmid><doi>10.1016/j.canep.2021.101929</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-2644-326X</orcidid><orcidid>https://orcid.org/0000-0003-4426-7236</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1877-7821 |
| ispartof | Cancer epidemiology, 2021-06, Vol.72, p.101929-101929, Article 101929 |
| issn | 1877-7821 1877-783X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2509266783 |
| source | Elsevier ScienceDirect Journals Complete - AutoHoldings; ProQuest Central UK/Ireland |
| subjects | Age Blood cancer Cancer Cancer therapies Epidemiology Haematological malignancies Hematology Leukemia Lymphoma Malignancy Myelodysplastic syndrome Myelodysplastic syndromes Non-Hodgkin's lymphoma Patients Population Standardised incidence ratio Subsequent primary tumour Survival Testicular cancer Time trends Trends Tumors |
| title | Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T10%3A54%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Significant%20current%20epidemiological%20trend:%20Haematological%20malignancies%20as%20subsequent%20primary%20tumours%20in%20cancer%20patients&rft.jtitle=Cancer%20epidemiology&rft.au=Pehalova,%20Lucie&rft.date=2021-06&rft.volume=72&rft.spage=101929&rft.epage=101929&rft.pages=101929-101929&rft.artnum=101929&rft.issn=1877-7821&rft.eissn=1877-783X&rft_id=info:doi/10.1016/j.canep.2021.101929&rft_dat=%3Cproquest_cross%3E2509266783%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2528428167&rft_id=info:pmid/33819838&rft_els_id=S1877782121000461&rfr_iscdi=true |